Non Hodgkin's LymphomaPhase 1/2NCT05370547
Chidamide Bridging for CAR-T Therapy
A Phase 1/2 study testing Chidamide, Fludarabine and cyclophosphamide and Anti-CD19 CAR-T cells in people with Non Hodgkin's Lymphoma, run by Chinese PLA General Hospital at 13 sites in China.
Trial summary
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Read more about this study
- Who is it for?
- Ages 16 to 75 years
- Conditions the study is for
- Non Hodgkin's Lymphoma
- What is being tested?
- Chidamide, Fludarabine and cyclophosphamide and Anti-CD19 CAR-T cells
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 13 sitesChina
- Study dates
- 25 May 2022to 30 Jun 2025
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age 16-75, male or female;
- Recurrent or refractory large B-cell lymphoma (LBCL) ,grade 1-3a follicular lymphoma (FL) and mantle cell lymphoma (MCL). Recurrent or refractory disease was defined as progression after systemic treatment with second-line or more lines (including CD20 monoclonal antibody and doxorubicin) or primary resistance (disease progression during first-line treatment or within 6 months after completion of treatment). LBCL includes diffuse large B-cell lymphoma non-specific type (DLBCL-NOS), diffuse large B-cell lymphoma transformed by follicular lymphoma (TFL), grade 3b FL, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma with MYC and Bcl-2 and/or Bcl-6 rearrangement ( double strike/triple hit lymphoma, DHL/THL);
- Eastern Cooperative Oncology Group (ECOG) physical status is 0-3;
- Life expectancy ≥12 weeks;
- Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide lymph node or tissue biopsy from the most recent available archived tissue for immunohistochemical NOXA testing and pathology review in the study center laboratory;
- There are measurable target lesions;
Show all 11Show fewer
- CD19 positive;
- Are willing to use contraception according to the following criteria:
- Women of reproductive age (15-49 years) must undergo a pregnancy test with negative results within 7 days before starting treatment; B. Women of reproductive age should use effective contraception for at least 120 days after the last dose of the study drug (contraceptive success rate of at least 99%). The subject should communicate with the available contraceptive methods with at least 99% success rate and confirm the understanding of the period; C. Male subjects used effective contraception for at least 93 days after the last dose of study drug (contraceptive success rate of at least 99%). The subject should communicate with the available contraceptive methods with at least 99% success rate and confirm the understanding of the period; D. Infertile women (i.e., surgically sterilized by hysterectomy and/or bilateral oophorectomy or amenorrhea ≥12 months and age > 45 years) are not subject to conditions A and B above
- Adequate bone marrow and organ functions (normal values shall not be obtained with growth factors, and hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions A, B, and C below) :
- Neutrophil count (ANC) ≥1.0×10^9/L; B. Hemoglobin ≥8.0g/dL; C. Platelet count ≥50×10^9/L; D. Total bilirubin ≤1.5× upper limit of normal value (ULN) (< 3 TIMES ULN for patients with Gilbert syndrome, cholestasis caused by hilar compression adenosis, biliary obstruction caused by liver involvement or lymphoma); E. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤2.5×ULN or ≤5×ULN when liver invasion is present; F. Creatinine clearance ≥40ml/min using the cockcroft-gault equation or glomerular filtration rate ≥40ml/min/1.73m2 using the modified renal disease diet formula; G. Lipase ≤1.5×ULN.
Who cannot join
- Patients known to be allergic to the drug Chidamide;
- Lymphoma involves the central nervous system;
- Known human immunodeficiency virus (HIV) infection or immunopositive test;
- Viral infections that cannot be controlled by antiviral drugs, such as herpetic virus infection, acute or chronic active hepatitis B, acute or chronic active hepatitis C, etc. [Note: chronic hepatitis B virus (HBV) carriers or non-active hepatitis B surface antigen (HBsAg) positive subjects and HBV-DNA lower than the detection limit can be included in the group; hepatitis C virus (HCV) antibody negative can be enrolled, HCV antibody positive patients need to be tested for HCV-RNA, if negative can be enrolled];
- Presence of active infectious disease requiring treatment;
- Received live vaccine within 30 days prior to enrollment;
Show all 20Show fewer
- Active autoimmune disease requiring systemic treatment within 12 months prior to enrollment (i.e., disease-modifying drugs, corticosteroids, or immunosuppressive drugs). Note: Alternative therapies (such as thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary dysfunction) are not considered a systemic treatment;
- History of severe allergic reactions;
- Presence of congestive heart failure or uncontrolled arrhythmias classified by the New York Heart Association as class III-IV;
- Patients with clinically significant electrocardiogram abnormalities and potential risk of malignant arrhythmias;
- Clinically significant cardiac events, including unstable angina, acute myocardial infarction, and/or cardiac transmission problems, occurred within 6 months prior to enrollment;
- A history of stroke or intracranial hemorrhage within 3 months prior to enrollment;
- Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered;
- Accompanied by uncontrolled major medical conditions, including, but not limited to, kidney, liver, blood, gastrointestinal, endocrine, pulmonary, neurological, brain or psychiatric disorders;
- Current or previous malignancy within 3 years prior to enrollment, excluding cured basal or squamous cell skin cancer, superficial bladder cancer, prostatic intraepithelial tumor and carcinoma in situ of the cervix;
- Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation;
- There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data;
- Pregnant or breast-feeding patients;
- Inability to swallow and retain oral medications, malabsorption syndrome, diseases that significantly affect gastrointestinal function, total resection of the stomach or small intestine, ulcerative colitis, symptomatic inflammatory bowel disease, partial or complete intestinal obstruction;
- Inability to understand or unwillingness to sign informed consent.
Trial locations and contacts
13 sites in 1 country.
13 sites in 1 country
China13 sites, 13 recruiting
- Recruiting
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality
Liang Wang, +86-010-58266699
- Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality
Wei Zhang, Ph.D, +86-010-69156114
- Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality
Zhitao Ying, Ph.D, +86-010-88121122, yingzhitao001@163.com
- Recruiting
Biotherapeutic Department, Chinese PLA General Hospital
Beijing
Weidong Han, Ph.D, +86-010-55499341, hanwdrsw@sina.com
- Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan
Ting Niu, Ph.D, +86-18980601242, tingniu@sina.com
- Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong
Yuhua Li, Ph.D, +86-020-61643888, liyuhua2011gz@163.com
- Recruiting
Sun Yat-Sen University Cancer Hospital
Guangzhou, Guangzhou
Qingqing Cai, Ph.D, +86-020-87343392
- Recruiting
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang
Wenbin Qian, Ph.D, +86-0571-88208277, qianwenb@aliyun.com
- Recruiting
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality
Aibin Liang, Ph.D, +86-021-66111019, Lab7182@tongji.edu.cn
- Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Suzhou
Caixia Li, Ph.D, +86-0512-65223637
- Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality
Huilai Zhang, Ph.D, 18622221228, zhlwgq@126.com
- Recruiting
Tongji Hospital, Tongji Medical College of HUST
Wuhan, Hubei
Liang Huang, Ph.D, +86-027-83662640, lhuang@tjh.tjmu.edu.cn
- Recruiting
Xiehe Hospital, Tongji Medical College of HUST
Wuhan, Hubei
Heng Mei, Ph.D, +86-027-85726114
About this study
Official title: A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.
Read the detailed description
Background:
CAR-T cell therapy has been shown to be superior to conventional therapy in patients with r/r B-cell NHL. However, prior clinical studies and real-world data suggest that approximately 30-40% of cases of drug resistance still occur after CAR-T cell therapy, and approximately 50-60% of cases have recurrent disease progression over time of infusion. The investigators used genome-wide CRISPR/Cas9 to screen for CAR T-resistant cells and identified low NOXA expression as associated with CAR-T resistance. NOXA protein is a member of the Bcl2 protein family, which plays a critical role in P53-dependent apoptosis. The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of CAR-T cells. Through the verification of nearly 40 clinical samples previously treated with CAR-T, the investigators found that low NOXA expression was associated with poor prognosis. Meanwhile, animal experiments demonstrated that HDACi can up-regulate the expression of NOXA in tumor cells and significantly improve the efficacy of CAR-T therapy by reducing the incidence of resistance. The research was published in Signal Transduction and Targeted Therapy in 2022.
Objective:
The primary objective of the study was to evaluate whether chidamide bridging intervention improved clinical response to CAR-T in patients with r/r B-cell NHL. A secondary objective was to evaluate the safety of bridging therapy with chidamide and subsequent CAR-T infusion in above patients. The exploratory objective was to investigate the effect of chidamide intervention on NOXA expression.
Design:
This is a multicenter, prospective, controlled, open-label, phase Ⅰ/Ⅱ study. 120 patients with r/r B-cell NHL will be enrolled. Biopsy was performed before peripheral blood mononuclear cell (PBMC) collection, and NOXA expression level was detected by immunohistochemistry (IHC).
Patients with high NOXA expression (IHC score > 4) were treated with conventional CAR-T process (n=60), including PBMC collection, bridging therapy (without chidamide), fludarabine and cyclophosphamide (FC) regimen conditioning, CAR-T cell infusion, efficacy evaluation and follow-up; Patients with low NOXA expression (IHC score 0 - 4) were randomly assigned 1:1 to conventional CAR-T group as mentioned earlier (n=30) or CAR-T group containing chidamide bridging therapy (n=30).
The bridging therapy regimen containing chidamide was divided into monotherapy and combination therapy. Chidamide combination intervention can be used in cases of high tumor burden, rapid progression of disease, symptoms of compression, involvement of specific sites or organs, and other burden reduction that need to be addressed. The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
In this study, commercial CAR-T cells (mainly Relma-cel, with Axi-cel or other commercial CAR-T cells also acceptable) or experimental CAR-T cells targeted at CD19 were acceptable.
If feasible, for the group with low NOXA expression, a secondary biopsy was performed at the same site to detect changes in NOXA expression before CAR-T infusion.
- Conditions
- Non Hodgkin's Lymphoma
- Being tested
- Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells
- Keywords
- CAR-T, NOXA, Chidamide
- Medical subject headings
- Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChidamideDrug
Also called HDACi
- Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.
- Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
Fludarabine and cyclophosphamideDrug
Also called FC regimen
Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m^2) and cyclophosphamide (250-500 mg/m^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
Anti-CD19 CAR-T cellsBiological
Also called Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells
A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10^6 for Relma-cel or 2 × 10^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
| Study group | Role | What they receive |
|---|---|---|
| high NOXA expression | Experimental | NOXA IHC score > 4; Bridging therapy was allowed but not containing chidamide; n=60. Receives: Drug: Fludarabine and cyclophosphamide; Biological: Anti-CD19 CAR-T cells |
| low NOXA expression and no chidamide intervention | Experimental | NOXA IHC score < 4; Bridging therapy was allowed but not containing chidamide; n=30. Receives: Drug: Fludarabine and cyclophosphamide; Biological: Anti-CD19 CAR-T cells |
| low NOXA expression and chidamide intervention | Experimental | NOXA IHC score < 4; Bridging therapy containing chidamide alone or combination; n=30. Receives: Drug: Chidamide; Drug: Fludarabine and cyclophosphamide; Biological: Anti-CD19 CAR-T cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants with progression-free survival (PFS) at 6 months after CAR-T infusion among all participants
PFS is defined as the time between the date of CAR-T infusion and disease progression or death from any cause. At the time of statistical analysis of study endpoints, there were no PFS events, and data were truncated as the date of the last objective tumor evaluation. Patients who were lost to follow-up or withdrew informed consent will be included in the end point evaluation, with data truncated as the date of the last objective tumor evaluation.
Measured: 6 months
Secondary outcomes (7)
Incidence of adverse events (AE) of chidamide bridging and subsequent CAR-T infusion arm
AE is defined as any adverse medical event from the time between the date of randomization and the date of 12 months after CAR-T infusion. AE may be an adverse sign (including abnormal laboratory tests, etc.), symptom, or illness that is not related to the purpose of medication and is time-related to drug use, regardless of causality to the drug, such as long-term cytopenia, cytokine release syndrome, neurotoxicity, etc.
Measured: 12 months
Participants with objective response rate (ORR) at 3 months after CAR-T infusion among all participants
ORR was defined as the percentage of subjects who achieved complete response or partial response assessed by investigators and based on the Lugano 2014 assessment criterion. All subjects who do not meet objective response criteria by the data analysis deadline will be considered nonresponders. The source of this endpoint will only include the assessment of response obtained after CAR-T infusion and prior to any additional antitumor therapy.
Measured: 3 months
Participants with complete response rate (CRR) at 3 months after CAR-T infusion among all participants
CRR was defined as the percentage of subjects who achieved a CR assessed by investigators and based on the Lugano 2014 assessment criterion.
Measured: 3 months
Percentage of participants with recurrence-free survival (RFS) at 6 months after CAR-T infusion among all participants
RFS was defined as the time between the date of CAR-T infusion and the date of first lymphoma recurrence (local, regional, distant metastasis) or death (whatever the cause) for subjects who received complete response after CAR-T infusion. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments.
Measured: 6 months
Percentage of participants with RFS at 12 months after CAR-T infusion among all participants
RFS was defined as above.
Measured: 12 months
Percentage of participants with PFS at 12 months after CAR-T infusion among all participants
PFS was defined as above.
Measured: 12 months
Percentage of participants with overall survival (OS) at 12 months after CAR-T infusion among all participants
OS was defined as the time between the date of CAR-T infusion and death from any cause.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2022
- Study start25 May 2022
- Primary completion30 Jun 2024 (estimated)
- Study completion30 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Hodgkin's LymphomaStudies of the same condition, open and under way.
- More trials run by Chinese PLA General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Han weidong, Chinese PLA General Hospital
- Investigators
- Weidong Han, Ph.D, Principal investigator, Biotherapeutic Department, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05370547
- Sponsor's protocol ID
- CHN-PLAGH-BT-071
- Status last verified
- Mar 2024
- First submitted
- 7 May 2022
- Last updated
- 6 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients
- ClinicalTrials.gov ID
- NCT05370547
- Acronym / sponsor ID
- CHN-PLAGH-BT-071
- Conditions
- Non Hodgkin's Lymphoma
- Keywords
- CAR-T, NOXA, Chidamide
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 25 May 2022 (actual)
- Primary completion
- 30 Jun 2024 (estimated)
- Study completion
- 30 Jun 2025 (estimated)
- First posted
- 11 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.
Detailed description
Background:
CAR-T cell therapy has been shown to be superior to conventional therapy in patients with r/r B-cell NHL. However, prior clinical studies and real-world data suggest that approximately 30-40% of cases of drug resistance still occur after CAR-T cell therapy, and approximately 50-60% of cases have recurrent disease progression over time of infusion. The investigators used genome-wide CRISPR/Cas9 to screen for CAR T-resistant cells and identified low NOXA expression as associated with CAR-T resistance. NOXA protein is a member of the Bcl2 protein family, which plays a critical role in P53-dependent apoptosis. The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of CAR-T cells. Through the verification of nearly 40 clinical samples previously treated with CAR-T, the investigators found that low NOXA expression was associated with poor prognosis. Meanwhile, animal experiments demonstrated that HDACi can up-regulate the expression of NOXA in tumor cells and significantly improve the efficacy of CAR-T therapy by reducing the incidence of resistance. The research was published in Signal Transduction and Targeted Therapy in 2022.
Objective:
The primary objective of the study was to evaluate whether chidamide bridging intervention improved clinical response to CAR-T in patients with r/r B-cell NHL. A secondary objective was to evaluate the safety of bridging therapy with chidamide and subsequent CAR-T infusion in above patients. The exploratory objective was to investigate the effect of chidamide intervention on NOXA expression.
Design:
This is a multicenter, prospective, controlled, open-label, phase Ⅰ/Ⅱ study. 120 patients with r/r B-cell NHL will be enrolled. Biopsy was performed before peripheral blood mononuclear cell (PBMC) collection, and NOXA expression level was detected by immunohistochemistry (IHC).
Patients with high NOXA expression (IHC score > 4) were treated with conventional CAR-T process (n=60), including PBMC collection, bridging therapy (without chidamide), fludarabine and cyclophosphamide (FC) regimen conditioning, CAR-T cell infusion, efficacy evaluation and follow-up; Patients with low NOXA expression (IHC score 0 - 4) were randomly assigned 1:1 to conventional CAR-T group as mentioned earlier (n=30) or CAR-T group containing chidamide bridging therapy (n=30).
The bridging therapy regimen containing chidamide was divided into monotherapy and combination therapy. Chidamide combination intervention can be used in cases of high tumor burden, rapid progression of disease, symptoms of compression, involvement of specific sites or organs, and other burden reduction that need to be addressed. The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
In this study, commercial CAR-T cells (mainly Relma-cel, with Axi-cel or other commercial CAR-T cells also acceptable) or experimental CAR-T cells targeted at CD19 were acceptable.
If feasible, for the group with low NOXA expression, a secondary biopsy was performed at the same site to detect changes in NOXA expression before CAR-T infusion.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| high NOXA expression | Experimental | Drug: Fludarabine and cyclophosphamide, Biological: Anti-CD19 CAR-T cellsNOXA IHC score > 4; Bridging therapy was allowed but not containing chidamide; n=60. |
| low NOXA expression and no chidamide intervention | Experimental | Drug: Fludarabine and cyclophosphamide, Biological: Anti-CD19 CAR-T cellsNOXA IHC score < 4; Bridging therapy was allowed but not containing chidamide; n=30. |
| low NOXA expression and chidamide intervention | Experimental | Drug: Chidamide, Drug: Fludarabine and cyclophosphamide, Biological: Anti-CD19 CAR-T cellsNOXA IHC score < 4; Bridging therapy containing chidamide alone or combination; n=30. |
Who may qualify
- Ages
- 16 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (11 listed)
- Age 16-75, male or female;
- Recurrent or refractory large B-cell lymphoma (LBCL) ,grade 1-3a follicular lymphoma (FL) and mantle cell lymphoma (MCL). Recurrent or refractory disease was defined as progression after systemic treatment with second-line or more lines (including CD20 monoclonal antibody and doxorubicin) or primary resistance (disease progression during first-line treatment or within 6 months after completion of treatment). LBCL includes diffuse large B-cell lymphoma non-specific type (DLBCL-NOS), diffuse large B-cell lymphoma transformed by follicular lymphoma (TFL), grade 3b FL, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma with MYC and Bcl-2 and/or Bcl-6 rearrangement ( double strike/triple hit lymphoma, DHL/THL);
- Eastern Cooperative Oncology Group (ECOG) physical status is 0-3;
- Life expectancy ≥12 weeks;
- Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide lymph node or tissue biopsy from the most recent available archived tissue for immunohistochemical NOXA testing and pathology review in the study center laboratory;
Key exclusion criteria (20 listed)
- Patients known to be allergic to the drug Chidamide;
- Lymphoma involves the central nervous system;
- Known human immunodeficiency virus (HIV) infection or immunopositive test;
- Viral infections that cannot be controlled by antiviral drugs, such as herpetic virus infection, acute or chronic active hepatitis B, acute or chronic active hepatitis C, etc. [Note: chronic hepatitis B virus (HBV) carriers or non-active hepatitis B surface antigen (HBsAg) positive subjects and HBV-DNA lower than the detection limit can be included in the group; hepatitis C virus (HCV) antibody negative can be enrolled, HCV antibody positive patients need to be tested for HCV-RNA, if negative can be enrolled];
- Presence of active infectious disease requiring treatment;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChidamideAlso: HDACi1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning. 2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc. | Drug | low NOXA expression and chidamide intervention |
| Fludarabine and cyclophosphamideAlso: FC regimenPatients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m^2) and cyclophosphamide (250-500 mg/m^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation. | Drug | high NOXA expression, low NOXA expression and chidamide intervention, low NOXA expression and no chidamide intervention |
| Anti-CD19 CAR-T cellsAlso: Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cellsA single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10^6 for Relma-cel or 2 × 10^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose. | Biological | high NOXA expression, low NOXA expression and chidamide intervention, low NOXA expression and no chidamide intervention |
Primary outcome
Percentage of participants with progression-free survival (PFS) at 6 months after CAR-T infusion among all participants
Time frame: 6 months
PFS is defined as the time between the date of CAR-T infusion and disease progression or death from any cause. At the time of statistical analysis of study endpoints, there were no PFS events, and data were truncated as the date of the last objective tumor evaluation. Patients who were lost to follow-up or withdrew informed consent will be included in the end point evaluation, with data truncated as the date of the last objective tumor evaluation.
7 secondary outcomes
Incidence of adverse events (AE) of chidamide bridging and subsequent CAR-T infusion arm
Time frame: 12 months
Participants with objective response rate (ORR) at 3 months after CAR-T infusion among all participants
Time frame: 3 months
Participants with complete response rate (CRR) at 3 months after CAR-T infusion among all participants
Time frame: 3 months
Percentage of participants with recurrence-free survival (RFS) at 6 months after CAR-T infusion among all participants
Time frame: 6 months
Percentage of participants with RFS at 12 months after CAR-T infusion among all participants
Time frame: 12 months
Percentage of participants with PFS at 12 months after CAR-T infusion among all participants
Time frame: 12 months
Percentage of participants with overall survival (OS) at 12 months after CAR-T infusion among all participants
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2024.
- Individual participant dataSharing planned: No
Related trials for Non Hodgkin's Lymphoma
RecruitingPhase 1/2
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Lymphoma, Non-Hodgkin
RecruitingPhase 1
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma
Active, not recruitingObservational study
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia
RecruitingObservational study
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Hematologic Malignancy, Leukemia
Active, not recruitingPhase 1/2
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Weidong Han, Ph.D principal investigator
Biotherapeutic Department, Chinese PLA General Hospital
13 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Chidamide, Fludarabine and cyclophosphamide and Anti-CD19 CAR-T cells in people with Non Hodgkin's Lymphoma, run by Chinese PLA General Hospital at 13 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Weidong Han, Ph.D (+86-10-55499341, hanwdrsw@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants with progression-free survival (PFS) at 6 months after CAR-T infusion among all participants (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2024.